Tumefactive multiple sclerosis and fingolimod Immunotherapies and unintended consequences

Neurology

Volumn 81, Issue 19, 2013, Pages 1648-1649

  Paul, Friedemann ^a   Bourdette, Dennis ^b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FINGOLIMOD; NATALIZUMAB; SPHINGOSINE 1 PHOSPHATE;

AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CIRCULATION; COMPETITIVE INHIBITION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; EDITORIAL; EFFECTOR CELL; HUMAN; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPH NODE; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; MULTIPLE SCLEROSIS; PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84888234144     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000435305.95271.84     Document Type: Editorial

References (8)

1. Pilz G, Harrer A, Wipfler P, et al. Tumefactive MS lesions under fingolimod: a case report and literature review. Neurology 2013;81:1654-1658.
2. Lucchinetti CF, Garvrilova RH, Metz I, et al. Clinical and radiologic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008;131:1759-1775.
3. Bourdette D, Gilden D. Fingolimod and multiple sclerosis: four cautionary tales. Neurology 2012;79:1942-1943.
4. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012;366:339-347.
5. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-1267.
6. Klein E, Bourdette D. Postmarketing adverse drug reactions: a duty to report? Neurol Clin Pract 2013;3:288-294.
7. Boster AL, Nicholas JA, Topalli I, et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol 2013;70:398-402.
8. Cohen JA, Coles AJ, Arnold AJ, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-1828.